Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Timothy Lopez"'
Autor:
Pasi A. Jänne, Prafulla C. Gokhale, Cloud P. Paweletz, Yang Qiu, Yasuki Kamai, Yoshinobu Shiose, Channing Yu, Paul T. Kirschmeier, Mari Kuraguchi, Luke J. Taus, Anika E. Adeni, Emily S. Chambers, Brittaney A. Leeper, Arrien A. Bertram, Elena V. Ivanova, Yutong Zhao, Kenneth Ngo, Tyler J. Teceno, Qing Zeng, Man Xu, Pinar O. Eser, Jens Köhler, Timothy Lopez, Heidi M. Haikala
Summary of EGFR inhibitor resistant patient-derived xenografts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dd2632c75c91725e2f6874eb406951b
https://doi.org/10.1158/0008-5472.22430896
https://doi.org/10.1158/0008-5472.22430896
Autor:
Pasi A. Jänne, Prafulla C. Gokhale, Cloud P. Paweletz, Yang Qiu, Yasuki Kamai, Yoshinobu Shiose, Channing Yu, Paul T. Kirschmeier, Mari Kuraguchi, Luke J. Taus, Anika E. Adeni, Emily S. Chambers, Brittaney A. Leeper, Arrien A. Bertram, Elena V. Ivanova, Yutong Zhao, Kenneth Ngo, Tyler J. Teceno, Qing Zeng, Man Xu, Pinar O. Eser, Jens Köhler, Timothy Lopez, Heidi M. Haikala
Antibodies used in the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac72ec6a0f9e1a1e4e15284228d95e18
https://doi.org/10.1158/0008-5472.22430899
https://doi.org/10.1158/0008-5472.22430899
Autor:
Pasi A. Jänne, Prafulla C. Gokhale, Cloud P. Paweletz, Yang Qiu, Yasuki Kamai, Yoshinobu Shiose, Channing Yu, Paul T. Kirschmeier, Mari Kuraguchi, Luke J. Taus, Anika E. Adeni, Emily S. Chambers, Brittaney A. Leeper, Arrien A. Bertram, Elena V. Ivanova, Yutong Zhao, Kenneth Ngo, Tyler J. Teceno, Qing Zeng, Man Xu, Pinar O. Eser, Jens Köhler, Timothy Lopez, Heidi M. Haikala
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for EGFR-mutant non–small cell lung cancers (NSCLC). However, most patients develop acquired drug resistance to EGFR TKIs. HER3 is a unique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65c6eaa7ce0560288d418189210ac24c
https://doi.org/10.1158/0008-5472.c.6513742.v1
https://doi.org/10.1158/0008-5472.c.6513742.v1
Autor:
Pasi A. Jänne, Prafulla C. Gokhale, Cloud P. Paweletz, Yang Qiu, Yasuki Kamai, Yoshinobu Shiose, Channing Yu, Paul T. Kirschmeier, Mari Kuraguchi, Luke J. Taus, Anika E. Adeni, Emily S. Chambers, Brittaney A. Leeper, Arrien A. Bertram, Elena V. Ivanova, Yutong Zhao, Kenneth Ngo, Tyler J. Teceno, Qing Zeng, Man Xu, Pinar O. Eser, Jens Köhler, Timothy Lopez, Heidi M. Haikala
Allelic Frequencies in PC-9 vs PC-9 T790M/C797S cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a816d548e9eae66b9e70111963fd67a4
https://doi.org/10.1158/0008-5472.22430893
https://doi.org/10.1158/0008-5472.22430893
Autor:
Pasi A. Jänne, Prafulla C. Gokhale, Cloud P. Paweletz, Yang Qiu, Yasuki Kamai, Yoshinobu Shiose, Channing Yu, Paul T. Kirschmeier, Mari Kuraguchi, Luke J. Taus, Anika E. Adeni, Emily S. Chambers, Brittaney A. Leeper, Arrien A. Bertram, Elena V. Ivanova, Yutong Zhao, Kenneth Ngo, Tyler J. Teceno, Qing Zeng, Man Xu, Pinar O. Eser, Jens Köhler, Timothy Lopez, Heidi M. Haikala
Supplementary Figures and legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf55805d887432d7c9a7ba07c91eb54
https://doi.org/10.1158/0008-5472.22430902.v1
https://doi.org/10.1158/0008-5472.22430902.v1
Autor:
Man Xu, Tyler Teceno, Pasi A. Jänne, Anika E. Adeni, Paul Kirschmeier, Timothy Lopez, Jens Köhler, Emily S. Chambers, Brittaney A Leeper, Mari Kuraguchi, Elena Ivanova, Arrien A. Bertram, Cloud P. Paweletz, Yoshinobu Shiose, Yutong Zhao, C. Yu, Yasuki Kamai, Luke J. Taus, Kenneth H. Ngo, Qing Zeng, Prafulla C. Gokhale, Heidi M. Haikala, Yang Qiu, Pinar O. Eser
Publikováno v:
Cancer Research. 82:130-141
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for EGFR-mutant non–small cell lung cancers (NSCLC). However, most patients develop acquired drug resistance to EGFR TKIs. HER3 is a unique
Autor:
Chi-Sing Ho, Sonal Khare, Madhavi Kannan, Michael Streit, Timothy Lopez, Luca Lonini, Brian Larsen, Brandon Mapes, Jenna Shaxted, Martin Stumpe, Ameen Salahudeen, Jagadish Venkataraman
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Pınar Özden, Eser, Raymond M, Paranal, Jieun, Son, Elena, Ivanova, Yanan, Kuang, Heidi M, Haikala, Ciric, To, Jeffrey J, Okoro, Kshiti H, Dholakia, Jihyun, Choi, Yoonji, Eum, Atsuko, Ogino, Pavlos, Missios, Dalia, Ercan, Man, Xu, Michael J, Poitras, Stephen, Wang, Kenneth, Ngo, Michael, Dills, Masahiko, Yanagita, Timothy, Lopez, Mika, Lin, Jeanelle, Tsai, Nicolas, Floch, Emily S, Chambers, Jennifer, Heng, Rana, Anjum, Alison D, Santucci, Kesi, Michael, Alwin G, Schuller, Darren, Cross, Paul D, Smith, Geoffrey R, Oxnard, David A, Barbie, Lynette M, Sholl, Magda, Bahcall, Sangeetha, Palakurthi, Prafulla C, Gokhale, Cloud P, Paweletz, George Q, Daley, Pasi A, Jänne
Publikováno v:
Science translational medicine
The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in EGFR-mutant non–small cell lung cancer is limited by the development of drug resistance. One mechanism of EGFR inhibitor resistance occurs through amplification
Autor:
Emily S. Chambers, Alwin Schuller, Stephen Wang, Dalia Ercan, Mika Lin, Pınar Özden Eser, Raymond M. Paranal, Nicolas Floc'h, Sangeetha Palakurthi, Alison D. Santucci, Jeffrey J. Okoro, Geoffrey R. Oxnard, Man Xu, Kenneth H. Ngo, Jeanelle Tsai, Ciric To, Lynette M. Sholl, George Q. Daley, Michael Dills, Pavlos Missios, Kesi Michael, Paul D. Smith, Yoonji Eum, Magda Bahcall, Yanan Kuang, David A. Barbie, Masahiko Yanagita, Jennifer C. Heng, Rana Anjum, Prafulla C. Gokhale, Elena Ivanova, Jieun Son, Kshiti Dholakia, Heidi M. Haikala, Darren Cross, Jihyun Choi, Michael J. Poitras, Pasi A. Jänne, Timothy Lopez, Cloud P. Paweletz, Atsuko Ogino
Publikováno v:
Science Translational Medicine. 13
A subset of drug-resistant EGFR -mutant MET -amplified lung cancer switches oncogenic dependence to MET and is treatable with MET inhibitor monotherapy.
Autor:
Pinar O. Eser, Yang Qiu, Jens Köhler, Yoshinobu Shiose, Timothy Lopez, Prafulla C. Gokhale, C. Yu, Man Xu, Heidi M. Haikala, Pasi A. Jänne
Publikováno v:
Cancer Research. 80:5192-5192
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have changed the treatment landscape for EGFR-mutant non-small cell lung cancers (NSCLC); however, most patients develop resistance over time. HER3 is a unique pseudokinase memb